News Quantified

OCUL – ocular therapeutix, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix (OCUL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds [Yahoo! Finance]

-3.8%

BEAT

-0.3%

MISS

-4.1%

MISS

Form 4 OCULAR THERAPEUTIX, INC For: Apr 09 Filed by: Dugel Pravin

Form SCHEDULE 13G/A OCULAR THERAPEUTIX, INC Filed by: VANGUARD GROUP INC

Form 8-K OCULAR THERAPEUTIX, INC For: Feb 27

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Dugel Pravin

Form 4 OCULAR THERAPEUTIX, INC For: Feb 23 Filed by: Kaiser Peter

Top News Gainers

3/17 Ocular Therapeutix Inc (NASDAQ: OCUL) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $8.00 price target on the stock. 21.1%

6/10 Form 4 OCULAR THERAPEUTIX, INC For: Jun 06 Filed by: Mattessich Antony C. 20.0%

3/3 Form 8-K OCULAR THERAPEUTIX, INC For: Mar 03 19.7%

6/6 Form 8-K OCULAR THERAPEUTIX, INC For: Jun 06 19.4%

5/30 Form 8-K OCULAR THERAPEUTIX, INC For: May 24 17.9%

3/20 Form 4 OCULAR THERAPEUTIX, INC For: Mar 18 Filed by: SUMMER ROAD LLC 15.6%

7/26 Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services 11.0%

3/12 Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31 10.5%

1/2 Form 4 OCULAR THERAPEUTIX, INC For: Dec 30 Filed by: Opaleye Management Inc. 10.1%

4/13 Form 8-K OCULAR THERAPEUTIX, INC For: Apr 13 9.0%

Top News Decliners

5/20 Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma -22.6%

2/25 Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference -16.3%

11/8 Form 8-K OCULAR THERAPEUTIX, INC For: Nov 06 -16.3%

11/12 Form 10-Q OCULAR THERAPEUTIX, INC For: Sep 30 -14.9%

11/14 Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference -12.2%

3/7 Ocular Therapeutix Inc (NASDAQ: OCUL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.6%

9/26 Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference -10.3%

1/10 Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: Opaleye Management Inc. -8.5%

11/15 Ocular Therapeutix Inc (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. -8.2%

8/7 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.420 ActVsEst (0.150) - Miss -8.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day